Unknown

Dataset Information

OS5.1 Phase I clinical trial with oncolytic virus DNX-2401 for DIPGs


ABSTRACT: Abstract

BACKGROUND

Despite our increased understanding of the genetic make-up and new therapies for pediatric high grade glioma (pHGG) and Diffuse Intrinsic Pontine Glioma (DIPG) the outcome remains grim. Delta-24-RGD (DNX-2401 in the clinic) has been tested for adult glioblastoma presenting a safe profile and promising efficacy. Recently our group has showed that the virus is safe and effective in preclinical models of pHGG and DIPG. Moreover, we showed that the virus is able to trigger an antitumor immune response. These outstanding preclinical results allowed us to propel a phase I clinical trial for newly diagnosed DIPGs (NCT03178032) where the patients received an intratumoral viral injection followed by standard radiotherapy.

MATERIALS AND METHODS

A phase I clinica

SUBMITTER: Alonso M 

PROVIDER: S-EPMC6795002 | biostudies-literature | 2019 Sep

REPOSITORIES: biostudies-literature